Long-term follow-up of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: a GRAALL study
Published inBiology of blood and marrow transplantation, vol. 19, no. 1, p. 150-155
Publication date2013
Abstract
Keywords
- Adolescent
- Adult
- Age Factors
- Antineoplastic Agents/administration & dosage/adverse effects
- Benzamides/administration & dosage/adverse effects
- Disease-Free Survival
- Female
- Follow-Up Studies
- Hematopoietic Stem Cell Transplantation
- Humans
- Male
- Middle Aged
- Philadelphia Chromosome
- Piperazines/administration & dosage/adverse effects
- Precursor Cell Lymphoblastic Leukemia-Lymphoma/mortality/therapy
- Pyrimidines/administration & dosage/adverse effects
- Survival Rate
- Time Factors
- Transplantation, Autologous
- Transplantation, Homologous
- Unrelated Donors
Affiliation entities
Citation (ISO format)
TANGUY-SCHMIDT, Aline et al. Long-term follow-up of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: a GRAALL study. In: Biology of blood and marrow transplantation, 2013, vol. 19, n° 1, p. 150–155. doi: 10.1016/j.bbmt.2012.08.021
Main files (1)
Article (Published version)
Identifiers
- PID : unige:37154
- DOI : 10.1016/j.bbmt.2012.08.021
- PMID : 22960387
Journal ISSN1083-8791